Christopher S Stauffer1, Jenna M Moschetto2, Scott McKernan2, Nathan Meinzer3, Chavy Chiang4, Rachel Rapier4, Elaine Hsiang5, Jerika Norona4, Brian Borsari2, Joshua D Woolley2. 1. San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America; Portland Veterans Affairs Medical Center & Oregon Health and Science University, United States of America. Electronic address: christopher.stauffer@va.gov. 2. San Francisco Veterans Affairs Medical Center, United States of America; University of California, San Francisco, United States of America. 3. Slalom Consulting, LLC, United States of America. 4. San Francisco Veterans Affairs Medical Center, United States of America. 5. University of California, San Francisco, United States of America.
Abstract
BACKGROUND: Methamphetamine (METH) use is a public health crisis that disproportionately affects men who have sex with men (MSM). There are currently no FDA-approved pharmacological interventions to treat methamphetamine use disorder (MUD). MUD is associated with social impairments and extremely high treatment attrition rates. Administration of oxytocin, a neuropeptide involved in social attachment, may be a novel approach to addressing these issues. Moreover, oxytocin administration has shown promise for reducing METH-related addictive behavior in animal models, but has not yet been investigated in clinical trials for MUD. Last, oxytocin is known to modulate stress responsivity via regulation of the autonomic nervous system, which is dysregulated in METH users. We hypothesize that oxytocin, in combination with group psychotherapy, will increase treatment engagement, reduce addiction behavior, and mitigate stress hyperreactivity. METHODS: This is a randomized, double blind trial of oxytocin 40-IU (n = 24) or placebo (n = 24) administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions for MUD in MSM. PRIMARY OUTCOME: (a) session attendance. SECONDARY OUTCOMES: (b) group cohesion, (c) anxiety, (d) METH craving, (e) METH use, and (f) in-session cardiac physiology. RESULTS: Participants receiving oxytocin had significantly higher group therapy attendance than those receiving placebo, OR 3.26, 95% CI [1.27-8.41], p = .014. There was a small effect of oxytocin on group cohension, but not anxiety or craving. METH use did not change over the six-week MIGT course in either treatment arm. Participants receiving oxytocin had lower average heart rates during MIGT sessions and higher heart rate variability. There were positive main effects of MIGT over Time regardless of study drug. CONCLUSIONS: This evidence, and the lack of any serious adverse events, suggests that oxytocin may safely increase treatment attendance. One possible mechanism by which it may do so is its modulation of the autonomic nervous system. Further investigation is warranted. Published by Elsevier Inc.
BACKGROUND: Methamphetamine (METH) use is a public health crisis that disproportionately affects men who have sex with men (MSM). There are currently no FDA-approved pharmacological interventions to treat methamphetamine use disorder (MUD). MUD is associated with social impairments and extremely high treatment attrition rates. Administration of oxytocin, a neuropeptide involved in social attachment, may be a novel approach to addressing these issues. Moreover, oxytocin administration has shown promise for reducing METH-related addictive behavior in animal models, but has not yet been investigated in clinical trials for MUD. Last, oxytocin is known to modulate stress responsivity via regulation of the autonomic nervous system, which is dysregulated in METH users. We hypothesize that oxytocin, in combination with group psychotherapy, will increase treatment engagement, reduce addiction behavior, and mitigate stress hyperreactivity. METHODS: This is a randomized, double blind trial of oxytocin 40-IU (n = 24) or placebo (n = 24) administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions for MUD in MSM. PRIMARY OUTCOME: (a) session attendance. SECONDARY OUTCOMES: (b) group cohesion, (c) anxiety, (d) METH craving, (e) METH use, and (f) in-session cardiac physiology. RESULTS: Participants receiving oxytocin had significantly higher group therapy attendance than those receiving placebo, OR 3.26, 95% CI [1.27-8.41], p = .014. There was a small effect of oxytocin on group cohension, but not anxiety or craving. METH use did not change over the six-week MIGT course in either treatment arm. Participants receiving oxytocin had lower average heart rates during MIGT sessions and higher heart rate variability. There were positive main effects of MIGT over Time regardless of study drug. CONCLUSIONS: This evidence, and the lack of any serious adverse events, suggests that oxytocin may safely increase treatment attendance. One possible mechanism by which it may do so is its modulation of the autonomic nervous system. Further investigation is warranted. Published by Elsevier Inc.
Entities:
Keywords:
Methamphetamine; Motivational interviewing; Oxytocin; Psychotherapy, group; Retention in care; Sexual and gender minorities
Authors: Keith A Hermanstyne; Glenn-Milo Santos; Eric Vittinghoff; Deirdre Santos; Grant Colfax; Phillip Coffin Journal: Drug Alcohol Depend Date: 2014-08-05 Impact factor: 4.492
Authors: Kathleen M Carroll; Samuel A Ball; Charla Nich; Steve Martino; Tami L Frankforter; Christiane Farentinos; Lynn E Kunkel; Susan K Mikulich-Gilbertson; Jon Morgenstern; Jeanne L Obert; Doug Polcin; Ned Snead; George E Woody Journal: Drug Alcohol Depend Date: 2005-09-28 Impact factor: 4.492
Authors: Kirsten C Morley; Jennifer L Cornish; Alon Faingold; Katie Wood; Paul S Haber Journal: Expert Opin Investig Drugs Date: 2017-04-07 Impact factor: 6.206
Authors: Thomas F Northrup; Charles Green; Robrina Walker; Tracy L Greer; Madhukar H Trivedi Journal: Addict Behav Date: 2014-11-25 Impact factor: 3.913
Authors: Amber N Edinoff; Elliot Thompson; Chandler E Merriman; Mark R Alvarez; E Saunders Alpaugh; Elyse M Cornett; Kevin S Murnane; Rachel L Kozinn; Mila Shah-Bruce; Adam M Kaye; Alan D Kaye Journal: Neurol Int Date: 2022-01-30
Authors: Katherine R Thorson; Scott M McKernan; Tessa V West; Joshua D Woolley; Wendy Berry Mendes; Christopher S Stauffer Journal: Sci Rep Date: 2021-10-25 Impact factor: 4.379
Authors: Christopher S Stauffer; Salem Samson; Alex Hickok; William F Hoffman; Steven L Batki Journal: Front Psychiatry Date: 2022-01-17 Impact factor: 5.435